Literature DB >> 28188887

Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: A systematic review.

Ana Adan1, Arantxa Y Arredondo2, Maria Del Mar Capella2, Gemma Prat2, Diego A Forero3, José Francisco Navarro4.   

Abstract

Recently there is a growing interest in the interaction of schizophrenia spectrum disorders (SSD) and substance use disorders (SUD), a condition named dual schizophrenia spectrum disorders (SSD+). While previous research has focused on clinical and cognitive aspects, little is known about the impact of comorbidity in the brain structure and functions. Evidence suggests that dual diagnosis patients, including SSD+, show a better neurocognitive functioning during the first years of illness, followed by a serious long-term decline. The initial search retrieved 94 articles, 12 were excluded for being redundant and 49 for not fulfilling the selection criteria. Thirty-three structural and functional neuroimaging studies that compare SSD and SSD+ patients were included. Both groups exhibited more brain alterations, in comparison to only SUD patients and healthy controls. SSD+ patients are less cognitively and emotionally impaired than non-dual SSD, but worse than healthy controls. The neurobiological alterations are prominent in SSD+ after five years of illness or longer. Moreover, SUD characteristics are important modulating factors, contrary to clinical severity or specific SSD diagnosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Comorbidity; Dual schizophrenia spectrum disorders; Illness duration; Neuroimaging; Schizophrenia; Schizophrenia spectrum disorders; Substance use disorders

Mesh:

Year:  2017        PMID: 28188887     DOI: 10.1016/j.neubiorev.2017.01.038

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  9 in total

Review 1.  Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Authors:  Kaloyan Rumenov Stoychev
Journal:  Front Psychiatry       Date:  2019-10-23       Impact factor: 4.157

Review 2.  Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders.

Authors:  David Crockford; Donald Addington
Journal:  Can J Psychiatry       Date:  2017-09       Impact factor: 4.356

3.  Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991-2016.

Authors:  S Florentin; Y Neumark; S Raskin; T Bdolah-Abram; P Rosca
Journal:  Adm Policy Ment Health       Date:  2021-03

4.  Polygenic risk for schizophrenia and season of birth within the UK Biobank cohort.

Authors:  Valentina Escott-Price; Daniel J Smith; Kimberley Kendall; Joey Ward; George Kirov; Michael J Owen; James Walters; Michael C O'Donovan
Journal:  Psychol Med       Date:  2018-03-04       Impact factor: 7.723

5.  Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach.

Authors:  Ying Hu; Zhonghai Fang; Yichen Yang; Dekai Rohlsen-Neal; Feng Cheng; Ju Wang
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

Review 6.  cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia.

Authors:  Haitao Wang; Jiangping Xu; Philip Lazarovici; Remi Quirion; Wenhua Zheng
Journal:  Front Mol Neurosci       Date:  2018-08-30       Impact factor: 5.639

7.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

8.  Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response.

Authors:  Ana Adan; José Francisco Navarro
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

9.  Metaphor Processing Dysfunctions in Schizophrenia Patients With and Without Substance Use Disorders.

Authors:  Ewa Karabanowicz; Ernest Tyburski; Karol Karasiewicz; Andrzej Sokołowski; Monika Mak; Monika Folkierska-Żukowska; Wioletta Radziwiłłowicz
Journal:  Front Psychiatry       Date:  2020-04-24       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.